glp-1 and general anesthesia Updated guidance for patients using GLP-1/GIP receptor agonists A very important and practice-changing

[3] Comparison of Available Options With multiple GLP-1 agonists available, healthcare providers and patients have the flexibility to choose the formulation that best suits their individual needs and preferences

XeCare has a deferred Massachusetts board matter from December 2025

Maximus Tribe caters to microdosers with rock-bottom rates for semaglutide ($79.99/mo) and tirzepatide ($99.99/mo), though it requires a 10-week commitment

Diabetic patients should have a baseline eye examination around the time of GLP-1/GIP agonist treatment initiation to determine the level of retinopathy and presence of DME

Understanding how long semaglutide treatment typically lasts provides context for this long-term planning

Common Application Mistakes to Avoid Knowing where to place GLP-1 patches is only half the battle